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Liver Graft-versus-host disease (GVHD) is common in patients with post-transplant
liver dysfunction following allogeneic hematopoietic stem cell transplantation
(AHSCT). Oftentimes, the diagnosis is made clinically, and liver biopsy is deferred.
Our objective was to evaluate the risk factors and clinical outcomes of liver GVHD
among patients who developed post-transplant liver dysfunction. Additionally, we
evaluated the feasibility of liver biopsy in this population. We compared outcomes
between liver GVHD and a “non-liver GVHD” group, which consisted of other etiolo-
gies of post-transplant liver dysfunction. Between January 2003 and December
2010, 249 patients developed post-transplant liver dysfunction following AHSCT:
124 patients developed liver GVHD and 125 were in the “non-liver GVHD” group.
The incidence of acute and chronic liver GVHD at one year was 15.7% and 31.0%,
respectively. The competing risk analysis revealed full intensity conditioning regimen
(Hazard ratio [HR], 1.76; P = .008) and related donor (HR, 1.68; P = .004) as inde-
pendent risk factors for liver GVHD. The time-varying covariate Cox regression
analysis with competing risk event, demonstrated that liver GVHD was indepen-
dently associated with higher non-relapse mortality, and adverse relapse-free and
overall survival. A total of 112 liver biopsies were performed in 100 patients. No
major complications were observed. Liver biopsy confirmed prebiopsy hypotheses
in 49% of cases, and led to treatment modification in 49% of patients. Our study
shows that liver GVHD is associated with adverse survival. Liver biopsy is safe
and often helps directing care in this setting.
1 | INTRODUCTION
Post-transplant liver dysfunction occurs in approximately 50%-80% of
patients following allogeneic hematopoietic stem cell transplantation
(AHSCT).1-3 Although this often raises the suspicion of liver GVHD,
other causes including chemotherapy, infection, sinusoidal
obstruction syndrome (SOS), reactivation of hepatitis, and iron over-
load may play an important role in the etiology of these abnormali-
ties.1,2,4-7 Understanding the cause is important as it affects the
treatment and outcomes. Classic liver GVHD, the most common
type, usually manifests with a cholestatic picture, including hyper-
bilirubinemia, and increase in alkaline phosphatase. These
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biochemical abnormalities associated with liver GVHD are often
seen in many other conditions, making the attestation of the cause
based on biochemical markers alone difficult. Traditionally bile duct
damage and portal lymphocyte infiltration on liver biopsy are
thought to be characteristic features of liver GVHD.8 However,
often liver biopsy is deferred because of concern of bleeding compli-
cations from transplant related coagulopathy and thrombocytopenia and
frequently, the diagnosis relies on clinical judgment. The current acute
liver GVHD grading by Glucksberg, et al, accounts for only total bilirubin
level, and identifies classic type of acute liver GVHD.9 Recently, a
hepatitic-variant of liver GVHD has been described, which presents as
an isolated AST or ALT elevation, more than 10 times normal.10 How-
ever, the Glucksberg scoring system, which does not take into account
transaminase elevations, does not recognize hepatitic-variants, and may
underestimate the true incidence of acute liver GVHD (1).
In the literature, only two studies have reported cumulative inci-
dences of acute and chronic liver GVHD, at 6.7% and 5.8%, respec-
tively.11,12 In general, the information on liver GVHD, and particularly
its impact on survival is limited. Moreover, prior studies evaluating the
safety of post-transplant liver biopsies in small numbers of patients
have shown increased morbidity.13-15 However, given the significant
advances made in the post-transplant patient management, imaging
and liver biopsy techniques, we assume that liver biopsy could safely
be performed in this population, and it may help direct further man-
agement. Our study evaluates incidence, risk factors and outcomes of
liver GVHD among patients with post-transplant liver dysfunction.
We also evaluated the safety and feasibility of liver biopsy in this
patient population.
2 | MATERIALS AND METHODS
We conducted a retrospective study of adult patients who underwent
AHSCT at Karmanos Cancer Institute (KCI) for hematologic malignan-
cies, between January 2003 and December 2010, and developed
post-transplant liver dysfunction. Post-transplant liver dysfunction
was defined as alanine aminotransferase (ALT), or aspartate amino-
transferase (AST) levels above twice the normal upper limit, or total
bilirubin level over 1.5 times the normal upper. The diagnosis of liver
GVHD was made after excluding common etiologies including alco-
holism, hepatitis (HBsAg, anti-hepatitis C antibody, herpes simplex,
varicella zoster virus, HHV6, HHV8, parvovirus), CMV or EBV viremia.
Also excluded were sepsis/systemic infection, drug-induced hepato-
toxicity, iron overload, sinusoidal obstruction syndrome (SOS) and
gallbladder pathology. Ultrasound of the abdomen was performed as
a part of the work up. The patients were divided into two groups,
namely liver GVHD and “non-liver GVHD”, and outcomes were com-
pared in both groups. Acute and chronic GVHD classification and
grading was as per physician discretion using standard criteria.9,16
Acute liver GVHD was defined as post-transplant liver dysfunction
occurring within or around day +100 post-transplant. Chronic liver
GVHD was defined as abnormalities in liver function beyond or
around day +100 post-transplant. All patients received ursodiol
starting a day prior to the preparative regimen and continued for the
first three months. We reviewed patients' records till last follow up
or death. This study was approved by the Wayne State University
Institutional Review Board.
Two pathologists from our institution evaluated the liver biopsy
samples using a scoring system based on our institutional criteria. At
least 10 portal areas were evaluated for features of liver GVHD,
including cholestasis, fibrosis, lobular inflammation, and iron
deposition. Liver GVHD was classified as grade 1 with minimal
lymphoplasmocytic infiltration of portal triads and/or lymphocytic
infiltration of some of the bile ducts. Grade 2 is mild to moderate
portal inflammation and/or involvement of most bile ducts. Grade
3 is moderate to severe portal inflammation and/or involvement
of most bile ducts in moderate degree, plus increased portal fibro-
sis or bile duct loss or lobular inflammation. Iron deposition was
classified as grade 0 (absent) as no stainable iron. Grade 1 (mild) as
rare foci with positive staining involving less than 5% of macro-
phages or hepatocytes. Grade 2 (moderate) is positive staining in
small foci involving less than 20% of macrophages or hepatocytes.
Grade 3 (severe) is positive staining in confluent patches involving
more than 20% of macrophages or hepatocytes.
2.1 | Preparative regimen
Full intensity conditioning regimens included (1) busulfan
(Bu) 130 mg/m2 (day −6 to −3),fludarabine (Flu) 30 mg/m2 (day −6
to −2); (2) BEAM ± R regimen consisted of carmustine 300 mg/m2
(day −7), etoposide (VP16), cytarabine both at 200 mg/m2/day (days
−6 to −3), and melphalan 140 mg/m2 (day −2), and ± rituximab
375 mg/m2 (day −8); (3) Bu/CY consisted of Bu 16 mg/kg oral
(day −7 to −4), cyclophosphamide (CY) 120 mg/kg daily (day −3 to
−2); (4) VP16/TBI consisted of etoposide 60 mg/kg (day-4) followed
by TBI 1200 cGY (day-2 to 0); (5) CY/TBI consisted of CY 120 mg/kg
(day −6 to −5) and TBI 1200 cGY (day −3 to −1); (6) BAC consisted of
Bu 4 mg/kg/day orally (day −8 to −5), Ara-C 2 g/M2 intravenously
every 12 hours (day −4 and − 3) (a total of 4 doses) and cyclophos-
phamide 60 mg/kg/d IV (day −2 and − 1).
Reduced intensity regimens included (1) busulfan 130 mg/m2
(day −6 and − 5)/Flu 30 mg/m2 (day −6 to −2)/TBI 200 cGy (day 0),
(2) Flu 30 mg/m2 (day −6 to −2)/melphalan 140 mg/m2 (day −2)/TBI
200 cGy (day 0) with or without rituximab, (3) Cy 60 mg/kg/day
(day −5 & -4)/Flu 25 mg/m2 (day −6 to −4)/TBI 220 cGy twice
daily (day −3 to −1), (4) Cy 60 mg/kg/day (day −4 and − 3)/Flu
30 mg/m2 (day −7 to −3).
2.2 | Statistical methods
This is a single institution retrospective study among patients who
developed liver dysfunction after AHSCT. The primary objectives
were to estimate the impact of liver GVHD on overall survival
(OS) and non-relapse mortality (NRM) compared to the “non-liver
GVHD” group. Other time to event endpoints, such as relapse-free
survival (RFS) and relapse were evaluated as well. As the liver
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GVHD events are post-transplant events, time-dependent
covariates (TDC), the Cox model was used to take this into
account. Acute and chronic liver GVHD were both modeled as
TDC. The effect of acute and/or chronic liver GVHD on OS, or
RFS, was assessed with the TDC Cox model, with starting time at
AHSCT. For NRM, the effect of acute and/or chronic liver GVHD
was assessed with the cause-specific TDC Cox model, with
competing event of relapse. For relapse, the effect of acute and/or
chronic liver GVHD was assessed with cause-specific TDC Cox
with competing event of NRM. All Cox models were adjusted for
the baseline conditioning regimen, disease risk index, donor type,
and CMV serostatus.
Secondary objectives were to assess cumulative incidence of liver
GVHD and its risk factors. As our population of interest, the post-
transplant liver dysfunction patients were unidentifiable at the time of
AHSCT. Our cumulative incidence of liver GVHD was descriptive, and
the incidence would be higher compared to all patients who underwent
AHSCT. The cumulative incidence of acute liver GVHD, and the cumu-
lative incidence of chronic liver GVHD were calculated with disease
relapse or NRM as competing risks. The risk factor for liver GVHD ana-
lyses was focused on association rather than prediction. This is similar
to the baseline risk analysis for treatment responders/non-responders,
who were unidentifiable pre-treatment. For baseline characteristics of
the retrospective cohort, patients with vs without liver GVHD, were
compared with Fisher's exact test for categorical data, and Wilcoxon's
rank sum test for continuous data. Fine and Gray competing risks
regression was used to assess the impact of baseline covariates on
cumulative incidence of liver GVHD, where the competing risks were
relapse or death. For patients who had both acute and chronic liver
GVHD, the time of acute liver GVHD was used in the risk analysis.
Our tertiary objectives were to describe the effect of iron over-
load on OS among liver GVHD patients, who underwent liver biopsy
and descriptive analyses on safety and utility of liver biopsy. The KM
plot and log-rank test among the three iron overload stages, were per-
formed with the starting time point of onset of acute or chronic liver
GVHD, whichever came first. Median follow up for OS was calculated
with the reverse KM method. The side-by-side boxplot and Bruskal-
Wallis test were performed. They were for a simple correlation
between the change of lab results from AHSCT, to the onset of liver
dysfunction, such as ALT, AST, ALP, and total bilirubin, They were also
to test clinical outcomes, such as NRM, relapse, and those alive with-
out relapse, in non-liver GVHD and liver GVHD subgroups. All
P values are 2-sided, and not adjusted for multiple testing, due to the
nature of this exploratory study. Statistical analysis was performed
using R version 3.3.2.
3 | RESULTS
A total of 249 patients developed post-transplant liver dysfunction
during the study period. One hundred twenty-four patients were
found to have acute and/or chronic liver GVHD, and 125 were in
the “non-liver GVHD” group (Table 1). Median age of the
population was 51 years. The most common indications for AHSCT
were AML (44%), MDS (16%) NHL (13%), and ALL (9%). Peripheral
blood was the most commonly used stem cell source (94%). Liver
GVHD patients were more likely to receive matched related AHSCT
compared to non-liver GVHD group (50% vs 34%; P = .015), while
the non-liver GVHD group was more likely to undergo matched
unrelated AHSCT (66% vs 50%). Liver GVHD patients more






(n = 125) P valuea
Age 51 (14,70) 52 (23,70) 0.246
Sex 0.128
Male 73 (59) 61 (49)
Female 51 (41) 64 (51)
Race 0.52
Caucasian 114 (92) 111 (89)
Black 8 (6) 13 (10)
Others 2 (2) 1 (1)
Diagnosis 0.913
AML 58 (47) 53 (42)
MDS 19 (15) 21 (17)
NHL 16 (13) 16 (13)
ALL 13 (10) 10 (8)
HKD 0 (0) 2 (2)
CLL 5 (4) 8 (6)
AAA 2 (2) 3 (2)
PLL 0 (0) 1 (1)
ANLL 1 (1) 0 (0)
MM 1 (1) 2 (2)
Myeloproliferative
disorder
9 (7) 9 (7)
Admit KPS 80 (60100) 80 (50100) 0.008
Comorbidity Index 1 (0,5) 1 (0,5) 0.537
Disease Risk Index 0.472
Low 10 (8) 8 (6)
Intermediate 73 (59) 65 (52)
High 36 (29) 48 (38)
Very High 5 (4) 4 (3)
Source of transplant 0.137
PBSC 120 (97) 115 (92)
BM 4 (3) 7 (6)
CB 0 (0) 3 (2)
Donor type 0.015
Allo Unrelated 62 (50) 82 (66)
Allo Related 62 (50) 43 (34)
Note: Continuous data are presented as median (range); categorical data
are expressed as the counts (percentage).
aFisher's exact test or Wilcoxon's rank sum test as appropriate.
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commonly received tacrolimus-mycophenolate (MMF) as GVHD pro-
phylaxis, compared to the non-liver GVHD group (94% vs 85%,
P = 004). The diagnosis of liver GVHD was made clinically in
44 patients, and pathologically through liver biopsy in 80 patients.
The median follow-up of surviving patients was 7.1 years (95% CI,
6.5-7.6). The common causes of death were infections (27%), disease
recurrence (22%), worsening chronic (18%) and acute (12%) GVHD,
multiorgan failure (3%), SOS (3%) and others (15%).
3.1 | Cumulative incidence of liver GVHD
Thirty-nine patients developed acute liver GVHD at a median of
57 days (range, 7-146) post-transplant. The cumulative incidence of
acute liver GVHD was 15.7% (95% CI, 11.5% -20.5%) at 6 months
(Figure 1). As per Glucksberg criteria, stage 1, stage 2, stage 3 and
stage 4 acute liver GVHD was observed in 18%, 13%, 18%, and 28%
patients, respectively. Twenty-three percent (n = 9) patients with
acute liver GVHD, did not have bilirubin elevation and the pathologi-
cal diagnosis was made in 60% of these patients. The rates of grade
II-IV and III-IV aGVHD of entire liver GVHD group were 52%, and
31%, respectively. Table S1 shows distribution of grade, stage and
organ involvement of aGVHD. Isolated liver GVHD was observed in
3.1% and 2.6% in grade II-IV and III-IV aGVHD, respectively
(Figure 1). Ninety-three patients developed chronic liver GVHD at a
median of 210 days (range, 103-1366) post-transplant, and one-year
cumulative incidence was 31.0% (95% CI, 25.3-36.8%), Figure 1.
Eighty four out of 93 patients (90%) had extensive and 9 (10%) had lim-
ited chronic GVHD. Four patients (3%) were diagnosed as hepatitic-
variant liver GVHD, and liver biopsy in three patients revealed evidence
of GVHD. The kinetics of AST, ALT, ALP, and total bilirubin in the liver
GVHD and non-liver GVHD group is shown in Tables 2–6. Liver GVHD
patients had significantly higher values of AST, ALT, ALP, and total bili-
rubin compared to non-liver GVHD group.
3.2 | Risk factors of liver GVHD
Admit Karnofsky Performance Score (KPS) (P = .008), donor type
(P = .015), and GVHD prophylaxis (0.0004) (Table 1) were risk factors
based on univariate analysis. The multivariate analysis demonstrated
that full intensity conditioning regimen (HR = 1.76, P = .008), and
matched related donor AHSCT (HR = 1.68 P = .004) were associated
with liver GVHD (Table S2).
3.3 | Infectious complications
There was no difference in infectious complications between the
liver GVHD and the non-liver GVHD group. Seventy-four of
124 patients (60%) with liver GVHD had positive systemic infec-
tions, compared to 78 of 125 patients (62%) in the non-liver GVHD
group. No episode of CMV or EBV reactivation was noted at the
time of onset of liver GVHD, or liver dysfunction in the non-liver
GVHD group. There was no difference in the rate of CMV or EBV
reactivations in both groups. Twenty-five patients with liver GVHD
had CMV reactivation, with a median CMV PCR of 2713 (range,
321-58 500), while 36 patients with non-liver GVHD group devel-







(n = 125) P valuea
Sex mismatch 0.242
Match 73 (59) 63 (50)
M-F 25 (20) 36 (29)
F-M 26 (21) 24 (19)
Unknown 0 (0) 2 (2)
ABO mismatch 0.863
Major mismatch 26 (21) 22 (18)
Minor mismatch 24 (19) 27 (22)
Matched 63 (51) 58 (46)
Bidirectional 3 (2) 4 (3)
Unknown 8 (6) 14 (11)
HLA match 0.074
8/8 123 (99) 118 (94)
7/8 0 (0) 2 (2)
< 7/8 1 (1) 5 (4)
CMV serostatus 0.98
+/+ 30 (24) 28 (22)
−/− 39 (31) 42 (34)
+/− 16 (13) 15 (12)
−/+ 39 (31) 40 (32)
Conditioning regimen 0.071e
Full-intensity
R-BEAM/BEAM 14 (11) 12 (10)
Busulfan-based regimen b 59 (48) 51 (41)
TBI based regimenc 10 (8) 14 (11)
BAC 11 (9) 4 (3)
Reduced-intensity
Bu based regimen 20 (16) 29 (23)
TBI based regimend 9 (7) 11 (9)
Flu-ATG/FLU-CY/
Flu-MEL-ATG
0 (0) 2 (2)
Cy-Flu-ATG 2 (2) 3 (2)
GVHD prophylaxis 0.004
Tacro/MMF 117 (94) 106 (85)
Tacro/SIR/Thymo 3 (2) 16 (13)
CSA/MTX 3 (2) 1 (1)
Tacro/MMF/Thymo 1 (1) 1 (1)
Tacro 0 (0) 1 (1)




dFlu-MEL-TBI, R-Flu-MEL-TBI, CY-Flu-TBI, R-BU-Flu-TBI.
eP value for testing difference between full-intensity and reduced intensity.
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258-146 000). Five patients with liver GVHD had EBV reactivation
with a median EBV PCR of 589 (range, 293-2749), while 11 patients
with non-liver GVHD had EBV reactivation with a median EBV PCR
of 432 (range, 205-1883).
3.4 | Impact of liver GVHD on survival, RFS, relapse
and NRM
Both acute and chronic liver GVHD were independent risk factors
for adverse NRM. The adverse impact of acute liver GVHD was
predominantly observed in grade III-IV aGVHD patients. Patients
with grade III-IV aGVHD with liver involvement had poor OS
(HR 3.65, P < 0.001), RFS (HR 3.62, P < 0.001) and NRM (HR 4.03,
P < 0.001), compared to grade III-IV aGVHD without liver involve-
ment (Table 7). Liver involvement does not moderate the effect
of chronic GVHD on OS or NRM. However, among patients
who had both grade III-IV aGVHD and chronic GVHD, those with
liver involvement had worse OS (HR 4.67, P < 0.001), RFS
(HR 4.43, P < 0.001) and NRM (6.16, P < 0.001), than without liver
F IGURE 1 Venn diagram
showing Liver, GI, and Skin
GVHD involvement in Grade II-IV
Acute GVHD (left) and Grade III-
IV Acute GVHD (right) for liver
GVHD group. Acute Liver GVHD
with relapse or NRM as
competing risks (bottom left).
Chronic Liver GVHD with relapse
or NRM as competing risks
(bottom right)
TABLE 2 Biochemical variables at
allogeneic transplant
With liver GVHD Non-liver GVHD
n Median (min, max) n Median (min, max) P valuea
AST 124 27 (8118) 123 28 (0.4402) 0.445
ALT 123 32 (12135) 121 28 (10350) 0.109
ALP 123 84 (43337) 121 88 (35866) 0.194
Total bilirubin 124 0.4 (0.1,3.4) 123 0.4 (0.1,2.4) 0.726
aWilcoxon's rank sum test.
TABLE 3 Biochemical variables at
peak between liver GVHD and non-liver
GVHD group
With Liver GVHD Non-Liver GVHD
n Median (min, max) n Median (min, max) P valuea
AST 123 201 (375404) 118 129 (334447) 0.003
ALT 123 274 (2317225) 118 162 (263500) 0.001
ALP 123 359 (732499) 118 193 (552402) <0.001
Total bilirubin 123 2.1 (0.3,50.4) 118 1.1 (0.1,42.4) <0.001
aWilcoxon's rank sum test.
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involvement. No adverse impact of liver GVHD on relapse was
noticed.
We plotted the distribution of the change of AST, ALT, ALP and
total bilirubin in liver GVHD and non-liver GVHD groups, from AHSCT
to onset of liver dysfunction. We divided patients into three groups:
alive without relapse, relapse and non-relapse mortality. Total bilirubin
level was significantly associated with higher NRM compared to AST,
ALT and ALP in both groups (Figure S1 and S2).
3.5 | Safety and utility of liver biopsy
One hundred twelve liver biopsies were performed during the study
period in 100 patients. Ninety patients underwent one biopsy, eight
patients had two biopsies and two had three liver biopsies, respectively
for liver dysfunction not improving after initial treatment. Biopsy
approach was transjugular (n = 106), percutaneous (n = 3) or laproscopic
(n = 3). The median time between AHSCT to liver biopsy was 175 days
(range, 21-1366). The median platelet count prior to biopsy was 121 000
per microliter (range, 10 000-418 000 per microliter). Seven patients had
platelets <50 000 per microliter, 36 had platelets between 50 000 and
100 000 per microliter and 67 had platelets >100 000 per microliter
at the time of biopsy. Twenty-three patients received platelet
transfusions with a median of 15 units (range, 1-40), whereas
10 patients received fresh frozen plasma with a median of four units
(range, 1-16) during the peri-biopsy period. Three patients experi-
enced hematoma and pneumothoraces following liver biopsy, and all
had platelet counts above 100 000 per microliter at the time of
biopsy. No mortality was observed.
A pathological diagnosis was made in all patients. Primary diagno-
ses were following: liver GVHD (n = 80), iron overload (n = 11), non-
alcoholic steatohepatitis (n = 7), acute non-viral hepatitis (n = 5), SOS
(n = 3), cholestasis (n = 5), viral hepatitis (n = 1), drug related liver
injury (n = 1), extrahepatic biliary obstruction (n = 1), and fibrosis
(n = 2). Seventy-six patients out of 80 with liver GVHD had evidence
of iron overload, and four patients had more than one pathology pre-
sent in the specimen. Following histologic stages of liver GVHD were
noted in liver biopsy specimens (n = 80 patients): stage I (n = 22,
28%), stage II (n = 43, 54%), and stage III (n = 15, 19%). Grade I, II, and
III iron overload was noted in 19%, 36%, 40% patients, respectively
(Table S3). The log rank test did not show any survival difference
among patients with grade I, II, and III iron overload (P = .57)
(Figure S3). In general, 1-2 hypotheses were generated prior to liver
biopsy, and the hypothesis was correct in 49% of cases. In 49% of cases
(55 out of 112 biopsies) biopsy results led to modification of the
TABLE 4 Biochemical variables at
allogeneic transplant between liver
biopsy and non-liver biopsy group
Liver biopsy Non-liver biopsy
n Median (min, max) n Median (min, max) P valuea
AST 99 27 (11,71) 147 28 (0.4124) 0.483
ALT 97 31 (14120) 146 29 (10350) 0.259
ALP 97 85 (43337) 146 86 (35304) 0.448
Total bilirubin 99 0.4 (0.1,3.4) 147 0.4 (0.1,2.4) 0.802
aWilcoxon's rank sum test.
TABLE 6 Biochemical variables at
peak of liver dysfunction between liver
biopsy and non-liver biopsy group
Liver biopsy Non-liver biopsy
n Median (min, max) n Median (min, max) P valuea
AST 80 231 (645404) 99 116 (333345) <0.001
ALT 80 352.5 (7017225) 99 143 (263500) <0.001
ALP 80 414.5 (732499) 99 181 (551819) <0.001
Total bilirubin 80 2.85 (0.4,50.4) 99 1 (0.1,42.4) <0.001
aWilcoxon's rank sum test.
TABLE 5 Biochemical variables at
the time of onset of liver dysfunction
between liver biopsy and non-liver
biopsy group
Liver biopsy Non-liver biopsy
n Median (min, max) n Median (min, max) P valuea
AST 85 173 (181425) 98 107.5 (173345) <0.001
ALT 85 223 (381998) 98 136.5 (183500) <0.001
ALP 85 273 (691229) 97 168 (221871) <0.001
Total bilirubin 85 1.3 (0.2,26.8) 98 0.85 (0.1,45) 0.026
aWilcoxon's rank sum test.



















































































































































































































































































































































































































































































































































































































































































































































































































































































































1078 MODI ET AL.
treatment. Based on biopsy results, immunosuppressive medications
were escalated in 14 patients and discontinued in four patients, ant-
iviral medications were started in two patients, phlebotomy was started
in 32 patients. Both phlebotomy initiation and immunosuppressive
medication escalation was performed in three patients. Systemic ste-
roid use was frequent and prolonged in patients with liver GVHD. The
median number of immunosuppressive therapies was two in liver
GVHD group. Ninety-five patients (77%) with liver GVHD responded
at a median of 35 days (range, 0-3706). The remaining 28 patients who
did not respond are deceased. One patient without response is alive.
4 | DISCUSSION
In this retrospective study, we present cumulative incidence, risk
factors, and clinical outcomes of liver GVHD among post-transplant
liver dysfunction patients. We evaluated safety and utility of liver
biopsy as well. To date, our study is one of the largest to evaluate
outcomes of both acute and chronic liver GVHD. Following impor-
tant findings can be made: (1) the incidence of acute and chronic
liver GVHD was 15.7% and 31.0%, respectively among patients
with post-transplant liver dysfunction, (2) liver biopsy is safe in
post-transplant period and modified treatment in 49% of cases,
(3) full intensity conditioning regimen and related donors were risk
factors for liver GVHD and (4) acute and chronic liver GVHD led to
adverse NRM and OS.
We observed higher incidences of acute and chronic liver
GVHD. In a study by Arai et al, the cumulative incidence of acute
liver GVHD was 6.7%, whereas Chen et al reported chronic liver
GVHD incidence rate at 5.8%.11,12 The difference in these rates
could be attributed to different populations. Our rates reflect inci-
dences among patients with post-transplant liver dysfunction,
whereas above mentioned studies included an entire cohort of
transplant patients. We think that stem cell source and GVHD pro-
phylaxis could have also contributed to this difference. Bone mar-
row was a predominant source of stem cells (>50% of patients)
in the Arai et al study, compared to peripheral blood stem cells
(97% of patients) in our study. Tacrolimus and mycophenolate was
a frequently used GVHD prophylaxis regimen. We have previously
demonstrated that use of tacrolimus and mycophenolate was asso-
ciated with relatively higher incidences of severe acute and chronic
GVHD, in matched related and unrelated donors with AHSCT.17
Hepatitic-variant liver GVHD was less frequently noticed in our
cohort: 3% in our study vs 36% in others.18 Although the informa-
tion on transplant characteristics of the prior study is not available,
the reason for the discrepancy could be the difference in condition-
ing regimen or supportive care. Isolated acute liver GVHD was
noted in 2.6-3.1% of patients in our cohort, which was in line with
prior studies.
Full intensity conditioning regimen and matched related donors
were risk factors for the development of liver GVHD. Busulfan
based full intensity conditioning regimen was predominantly
used in our cohort. Studies have shown that busulfan is a potent
hepatotoxic agent. Higher incidence of veno-occlusive disease and
chronic GVHD was noted in patients treated with busulfan com-
pared to TBI.19 Moreover, myeloablative regimens are shown to
cause higher rate of grade II-IV acute GVHD and chronic GVHD.
This effect could partly be related to cytokine storm arising from
the pronounced GI mucosal injury.20 Matched related donor was
emerged as a risk factor for liver GVHD. The precise mechanism is
unclear. However, similar finding was noticed in a study by Arai
et al.11 Our study also reveals that liver GVHD is an independent
risk factor for adverse NRM and survival. This effect was pro-
nounced in grade III-IV aGVHD, while a positive trend was noted in
chronic liver GVHD. Unlike our study, few previous reports
showed adverse prognosis of acute liver GVHD in all grades of
aGVHD.11,21,22 This difference could be related to relatively
smaller sample size in our study. The adverse NRM and survival
could be related to prolonged use of systemic steroids and immu-
nosuppressive medications.
Post-transplant liver dysfunction is common after AHSCT and
reflects underlying liver injury. Majority of the times, physicians
tend to assign diagnosis based on clinical suspicion. However, in
cases with no clear diagnosis based on clinical, laboratory or radio-
logic imaging results, liver biopsy was performed. Our study rev-
ealed a different diagnosis than the one hypothesized before liver
biopsy in half of the cases and liver biopsy led to change in man-
agement in 49% of cases. In an another study evaluating liver
biopsy results, the correlation between pre- and post-liver biopsy
diagnosis was noted in 34% of cases and treatment modification
was made in 65% of cases following liver biopsy.23 Few other stud-
ies have reported treatment modifications in 37% to 66% of cases
following liver biopsy.13-15,24 This indicates that liver biopsy should
be considered when uncertainty in diagnosis prevails. Except for
bleeding complications occurring in a minority of patients (2.7%),
no major complications were observed. No bleeding complications
occurred in patients with platelets below 50 000 per microliter,
which indicates that liver biopsy can be safely performed despite
lower platelet counts.25,26 This could be due to transjugular liver
biopsies which is associated with less complications.27 Conversely,
previous reports have noted severe hemorrhages, subcapsular
bleeding, cardiac arrythmia, ICU admissions and procedure related
deaths.13-15 Another study reported 3% complication rate follow-
ing percutaneous liver biopsies.28
In conclusion, liver GVHD is the most common etiology of post-
transplant liver dysfunction and associated with adverse survival. Liver
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